In the ongoing quest to devise more effective cancer therapies, a newly published study from Northwestern Polytechnical University and its collaborative institutions introduces a pioneering approach that targets tumor metabolism with remarkable precision. This innovative research addresses a critical challenge in the emerging field of cuproptosis-based cancer treatment: the metabolic adaptability of cancer cells. Traditionally, copper-induced mitochondrial stress has demonstrated potential to eradicate cancer cells. However, many tumors exhibit metabolic plasticity, enabling them to pivot towards aerobic glycolysis—a metabolic pathway that allows survival despite mitochondrial damage. The study unveils an ingenious dual-targeting strategy designed to simultaneously disrupt both metabolic pathways, maximizing therapeutic efficacy.
At the core of this breakthrough are multifunctional copper-based nano-PROTACs, referred to as CHNDs. These nanoscale agents seamlessly integrate targeted protein degradation technology with copper-mediated cytotoxicity. The molecular target of this system is hexokinase 2 (HK-2), a pivotal enzyme responsible for initiating glycolysis by phosphorylating glucose. HK-2 is heavily exploited by rapidly proliferating cancer cells to sustain their elevated metabolic demands. Unlike conventional inhibitors, CHNDs harness the power of proteolysis targeting chimeras (PROTACs) to degrade HK-2, thereby effectively precluding the enzyme’s compensatory activation and quelling glycolytic flux with superior potency.
The initial step in the researchers’ design involved engineering PEI-based HK-2 degraders, dubbed PHDs. These molecular constructs are composed of a 3-bromopyruvate moiety—a covalent warhead that specifically binds to HK-2—linked to a thalidomide derivative, which acts as a recruiting ligand for the cereblon E3 ubiquitin ligase. This architectural assembly orchestrates proximity-induced ubiquitination, guiding HK-2 to the proteasome for rapid degradation. Experimental application in murine 4T1 breast cancer and CT26 colon cancer cell models confirmed that PHD treatment resulted in a significant diminution of HK-2 protein levels, reducing expression by over 40%, which translated into marked inhibition of glycolytic activity.
Building upon this foundation, the research team developed the CHND platform by adorning copper-based metal–organic framework (MOF) nanoparticles with polyethylene glycol (PEG)-linked PHDs. This design ensures nanoparticle stability within the bloodstream while enabling the preferential release of bioactive components in the acidic and glutathione-rich microenvironment characteristic of tumors. Upon accumulation in cancerous tissue, the CHNDs disassemble, releasing copper ions alongside PEG-PHD conjugates. The liberated PEG-PHDs perpetuate the degradation of HK-2, curtailing glycolysis, while copper ions initiate mitochondrial perturbations. This triggers cuproptosis, a unique form of cell death distinguished by DLAT protein aggregation and disturbance of iron–sulfur cluster proteins critical for mitochondrial function.
Cellular assays vividly demonstrated that CHND treatment surpassed the efficacy of either copper nanoparticles or HK-2 degraders alone. The combinatorial therapy led to pronounced suppression of glycolytic flux and reduced lactate production, key indicators of disrupted energy metabolism. Concurrently, intracellular ATP levels plummeted, reactive oxygen species surged, and mitochondrial membrane potential dissipated, hallmarks of mitochondrial distress. Moreover, DLAT aggregation was amplified, further corroborating the activation of cuproptotic pathways. These multifaceted perturbations showcase the potency of CHNDs in orchestrating dual metabolic inhibition.
Delving deeper into the mechanistic underpinnings, transcriptomic profiling of CHND-treated cancer cells unveiled widespread dysregulation across multiple biological processes. Genes implicated in proteasome activity, ubiquitin-mediated proteolysis, and endoplasmic reticulum protein processing were notably disrupted, indicating substantial disturbance in protein homeostasis. Additionally, pathways governing oxidative stress responses, mitochondrial respiratory chain assembly, and oxidative phosphorylation were profoundly affected, underscoring the comprehensive assault on cellular redox balance and bioenergetics. These transcriptomic insights reinforce the concept that CHNDs execute their antitumor effects by coordinating a simultaneous collapse of metabolic, proteostatic, and redox networks essential for cancer cell survival.
Translating these findings in vivo, the study employed several murine tumor models to evaluate therapeutic efficacy. In orthotopic 4T1 breast cancer models, CHND administration led to a striking 55.3% reduction in tumor volume. Even more compelling, in CT26 colon carcinoma models, tumor inhibition reached a substantial 76.6%, accompanied by a significant extension of median survival from 21 to 29 days. Remarkably, a subset of animals treated with CHNDs survived beyond 100 days, highlighting the potential for durable therapeutic responses. Histopathological analyses of excised tumors corroborated these outcomes by demonstrating pronounced HK-2 depletion, enhanced DLAT aggregation, and elevated indicators of tumor cell apoptosis.
The impact of CHNDs extended beyond primary tumors, revealing promising antimetastatic activity. In a spontaneous lung metastasis model derived from 4T1 breast cancer cells, animals receiving CHND treatment exhibited markedly reduced bioluminescent signals in lung tissue, alongside fewer metastatic nodules upon gross examination. These findings suggest that impairing glycolytic compensation and mitochondrial function collectively stymie not only tumor growth but also metastatic dissemination—an important advantage given the lethality of metastatic disease in clinical oncology.
Importantly, the study situates itself at the intersection of metal-ion cytotoxicity and targeted protein degradation—two therapeutic strategies that have historically advanced along separate tracks. CHNDs embody a novel paradigm by merging these modalities within a single nanoplatform, effectively converting copper from a mere cytotoxic agent to an integral component of a precision metabolic intervention. This synergistic approach capitalizes on the inherent vulnerabilities of cancer metabolism, specifically the reliance on HK-2-driven glycolysis and mitochondrial respiration, pushing cancer cells beyond the limits of metabolic plasticity.
Despite these compelling preclinical results, the path to clinical application will require further investigations. Key challenges include evaluating long-term implications of metal ion accumulation, potential immunogenicity of the metal-organic nanoparticles, pharmacokinetic profiles, and intertumoral heterogeneity that may influence therapeutic response. Additionally, rigorous safety assessments in larger animal models will be critical to address off-target effects and ensure tolerability. Nonetheless, the study’s conceptual advancement sets the stage for future translational efforts aiming to refine and harness integrated metabolic cancer therapies.
As a methodical example of engineering multifunctional nanotherapeutics capable of targeted protein degradation coupled with metal ion-induced cell death, this work heralds a new horizon in precision oncology. The elegant coupling of HK-2 degradation and cuproptosis induction illustrates the power of simultaneous multi-route blockade of cancer metabolism. Such integrative strategies offer hope in overcoming the formidable challenge posed by metabolic adaptability—a hallmark of malignant neoplasms—and may ultimately catalyze the development of next-generation treatments that improve patient outcomes and survival.
In summary, the development of CHNDs exemplifies a landmark advancement in multifunctional nanomedicine, where metabolic inflexibility is exploited for therapeutic gain. By joining copper-triggered mitochondrial stress with the targeted degradation of a glycolytic gatekeeper, this nanoplatform disrupts the core energetic and proteostatic infrastructure required for tumor sustenance. This synergistic assault on malignancy validates the strategy of coupling metal-induced cuproptosis with degradation of glycolytic enzymes as a powerful approach to cancer treatment, offering a promising avenue for future research and clinical translation.
Subject of Research: Not applicable
Article Title: Multifunctional Engineered Metal–Organic Frameworks as Targeted Protein Degraders for Augmenting Cancer Therapy via Hexokinase 2 Degradation and Provoking Cuproptosis
News Publication Date: 31-Mar-2026
Web References: 10.34133/research.1217
Keywords: cuproptosis, cancer metabolism, hexokinase 2, targeted protein degradation, metal–organic frameworks, nanomedicine, glycolysis inhibition, mitochondrial stress, 3-bromopyruvate, copper ions, reactive oxygen species, proteostasis
Tags: advanced cancer treatment strategiescancer metabolism targetingcopper-based nano-PROTACscuproptosis cancer therapydual metabolic pathway disruptionglycolysis inhibition in cancerhexokinase 2 degradationmetabolic plasticity of cancer cellsmitochondrial stress in tumorsnano-PROTAC drug delivery systemsproteolysis targeting chimeras in oncologytumor metabolic adaptability
